US6701002056 - ADR
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (5/17/2024, 7:17:01 PM)
After market: 131.65 -0.24 (-0.18%)131.89
-1.15 (-0.86%)
Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
NOVO-NORDISK A/S-SPONS ADR
Novo Alle 1
Bagsvaerd 2880
P: 4544448888
CEO: Lars Fruergaard Jorgensen
Employees: 61412
Website: https://www.novonordisk.com/
The market has flashed a green signal to investors.
Novo Nordisk's stock may look expensive today, but that may not be the case in even a year or two.
Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason.
Could Amgen be the next stock to soar due to a GLP-1 drug?
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing?
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
Here you can normally see the latest stock twits on NVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: